Scientists just resurrected enzymes that cannabis plants stopped using thousands of years ago — and they're proving far more useful than the specialized versions nature settled on.
Researchers at Wageningen University in the Netherlands used ancestral sequence reconstruction to rebuild cannabinoid-producing enzymes from early cannabis ancestors. What they found was counterintuitive: these ancient versions were generalists, capable of producing multiple compounds from a single starting material. Modern cannabis enzymes, by contrast, are specialists — each one locked into making a specific cannabinoid like THC or CBD.
"What once seemed evolutionarily unfinished turns out to be highly useful," says Robin van Velzen, one of the researchers. "These ancestral enzymes are more robust and flexible than their descendants, which makes them very attractive starting points for new applications in biotechnology and pharmaceutical research."
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThe CBC Opportunity
This flexibility opens a particular door: cannabichromene, or CBC. While THC and CBD dominate cannabis research and markets, CBC has quietly emerged as a promising therapeutic compound with potential anti-inflammatory, anticonvulsant, and antibacterial properties. The problem is that modern cannabis plants naturally contain less than 1% CBC, making it nearly impossible to study or extract at meaningful scale.
There's no cannabis plant alive today with naturally high CBC content. But if researchers introduce these resurrected ancestral enzymes into cannabis plants, they could breed varieties that produce CBC in clinically useful quantities — without waiting for natural evolution to stumble onto the same solution twice.
The real breakthrough, though, might be even simpler. The team discovered that these ancient enzymes are far easier to manufacture in microorganisms like yeast cells than modern cannabis enzymes are. That means pharmaceutical companies could potentially skip plant cultivation altogether and produce rare cannabinoids in fermentation tanks instead — faster, cheaper, and at scale.
The research, published in the Plant Biotechnology Journal, represents a shift in how scientists think about drug development from plants. Rather than accepting what nature currently offers, they're reaching back into evolutionary history to recover tools that worked better for different purposes. It's a reminder that sometimes the most innovative solutions aren't new at all — they're just forgotten.
